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FUNCTIONAL ANATOMY, FINE STRUCTURE AND 
BASIC PATHOLOGY OF RETINAL VASCULATURE 
1. Anatomical organization of retinal vasculature 
The retinal vasculature is arranged in 3 dimensional network. The 
central retinal artery is a direct branch of the ophthalmic artery arising 
from bifurcations adjacent to the optic disc to form a unique, intra retinal, 
end artery micro vascular system. 
Oxygen tension in the inner retina has been identified as a key 
regulator of retinal cell differentiation and micro vascular permeability, 
growth and survival by altering expression of VEGF. 
In the mature retinal micro vasculature this oxygen regulated 
control of capillary density is well illustrated by the appearance of a so 
called “capillary free zone”. Adjacent to arterial walls where oxygen 
tension is high and local expression of VEGF is low. 
Cilio retinal arteries may also contribute to the retinal circulation 
and these arise from posterior ciliary arteries. 
Branch retinal arteries lack an internal elastic lamina and 
anatomically speaking arterioles. These arterioles in the peripheral retina 
bifurcate to third and fourth orders and finally to pre capillary arterioles. 
The peri papillary retina has four layers of capillaries while the macular 
and peripheral retinas have three and two respectively. There is a 
capillary free zone at the fovea where the inner retinal neurons and their 
processes show lateral displacement to allow unobstructed passage of 
light to the midget central cones for accurate resolution of visual images. 
Each capillary unit is 10-15 micro meters in diameter and consists 
of continuous endothelium surrounded by pericytes. Retinal pericytes 
occur in a 1:1 ratio with endothelial cells which is the unique feature of 
this micro vasculature. 
The capillary flow drains into the venular system which is localized 
in the deeper retina and eventually into the retinal veins. The central 
retinal vein lies with in the optic nerve head and is drained by the 
ophthalmic vein and cavernous sinus. 
While the retinal vasculature is a classic end artery system, it lacks 
any obvious autonomic nerve supply and blood flow in to the capillary 
bed is auto regulated in response to the local metabolic needs of the 
retinal parenchyma. 
An important normal physiological function of the retinal 
vasculature is maintenance of the inner blood retinal barrier, which 
prevents non specific permeation of the retinal neuropile by 
macromolecules yet facilitates exchange of respiratory gases, amino 
acids, salts, sugars and peptides.  The endothelial cells of the retinal 
vessels form a continuous, non fenestrated, mono layer, with each cell 
being fused to juxta posed neighbours by zonulae occludens that maintain 
barrier function. 
2.  Responses of the retinal vasculature to stress and disease 
A.  Hemodynamic changes: 
Increased arteriolar intra luminal pressure induces reactive vessel 
narrowing probably by stretch activated calcium channels which may 
lead to occlusion of pre arteriolar branches, subsequent to endothelial 
damage and insudation of plasma in to the vessel wall. Occlusion of 
down stream retinal vessels may cause impaired axoplasmic transport 
clinically manifested as cotton wool spots and electron microscopy 
reveals swollen axons containing cytoid bodies in the nerve fiber layer. 
Normalization of intra vascular pressure results in recovery of 
competence and sometimes local reorganization of the effected micro 
vasculature, but the legacy of focal capillary drop out often persists in the 
form of micro aneurysms, persistent inner retinal exudates and focal 
reactive micro gliosis. Sudden increase in venous intra luminal pressure 
results in CRVO/ BRVO, in such case blood is shunted into the non 
obstructed circulation via competent capillary/ venular collaterals. Retinal 
arteriole macro aneurysms may reflect long standing arteriolar stress in 
patients with hyper tension.  The area of abnormally perfused retina is 
sufficiently large, ischemic/ hypoxic/ metabolically compromised retina 
can produce a range of angiogenic growth factors and leads to pre retinal 
/optic disc / iris / anterior chamber angle neo vascularisation. 
B. Oxygen saturation changes 
Reduced oxygen saturation rapidly affects the metabolically 
demanding retinal neuropile, which can release metabolites such as 
adenosine and lactate, and this triggers local vaso dilatation and increased 
blood flow as a direct consequence of vasogenic agents. Sustained 
hyperoxia has an exaggerated effect on immature retinal vessels with 
vascular closure and death of growth factor sensitive retinal vascular 
cells. Similarly chronic hypoxia induces vascular endothelial cell 
proliferation to revascularise metabolically deprived retina causes pre 
retinal neovascularization. 
C. Occlusion- ischemia 
Collapse of circulation is characterized by dilated capillaries, veno-
venous shunts, micro aneurysms, advential sclerosis and areas of 
capillary closure. These disorders can lead to focal retinal ischemia and 
significant damage in the form of macular edema, cystiod degeneration, 
focal atrophy of macular photo receptors, glial cell abnormalities and 
patho physiological changes in the RPE. 
D. Repair and remodeling 
Micro vascular repair and remodeling are a feature of acute and 
chronic vaso occlusion where there is continuing stasis, hypoxia and 
variations in tissue perfusion pressure. Capillaries dilate or attenuate and 
micro aneurysms form and subsequently show a pattern of sclerosis or 
recanalisation. A limited degree of intra retinal neo vascularisation occurs 
where redundant and acellular basement membrane tubes are recanalised 
and connect with residual radicals of the existing circulation. The form 
and orientation of these new vessels is determined by concentration 
gradients of growth factors, e.g., VEGF, TGF- beta and availability of 
angiogenic stem cells. 
E. Metabolic stresses 
The retinal micro vasculature can be influenced by a range of 
systemic disorders the most common being diabetes. Retinal vascular 
dysfunction commences soon after the onset of diabetes and is 
characterized by impaired auto regulation in the micro vasculature. The 
changes that manifest include basement membrane thickening, pericyte 
loss with formation of acellular capillaries corresponding to non perfused 
micro vasculature. Increasing closure of capillaries may be linked with 
cotton wool spots in the neural retina and also the occurrence of intra 
retinal micro vascular abnormalities. They could reflect increasing retinal 
ischemia and an attempt to revascularise hypoxic neuropile, possibly to 
form shunt like channels. Hypoxia increase expression of VEGF and 
other peptide growth factors that have an important modulatory role in 
the development of macular edema and pre retinal neo vascularisation. 
F. Primary neuropile atrophy and degeneration 
Normal function of the retinal circulation is completely dependent 
on intimate cell-cell communication with neural and glial elements of the 
retina. In retinitis pigmentosa, trauma, toxic retinopathy and loss of 
retinal parenchyma are associated with retinal capillary cell attrition, 
closure of capillary beds, narrowing of supply vessels and involutional 
sclerosis of larger radicals. 
RETINAL VASCULAR DEVELOPMENT 
1. Introduction 
Blood vessel formation occurs by three processes, the initial 
formation of vessels from yolk sacs during early embryogenesis, and by 
the distinct process of vasculogenesis and angiogenesis during subsequent 
development. 
YOLK SACS 
Angiogenic clusters containing hematopoietic cells at the centre 
and angioblasts lining the periphery. 
VASCULOGENESIS 
The assembly of vessels from separate endothelial precursor cells 
as they differentiate into mature endothelial cells. 
ANGIOGENESIS 
The formation of new blood vessels from preexisting capillaries. 
Differentiated endothelial cells are induced to proliferate, thus facilitating 
the sprouting of new vessels from existing vessels. 
2.  ENDOTHELIAL CELLS 
Form the vessel wall creating the lumen through which blood 
flows. The types are Continuous, Fenestrated, and Discontinuous. The 
retinal vasculature is continuous type which helps to regulate the neural 
microenvironment by protecting the retina from fluctuations in plasma 
composition, whereas choroidal vasculature is fenestrated. 
3.  MURAL CELLS 
Perivascular cells that associate with the vessels and lie just 
external to the endothelial cells. Appropriate recruitment of the various 
mural cells is important for stabilization and maturation of new vessels 
during developmental neovascularisation. Vessels lacking mural cells 
have been found to be most susceptible to apoptosis and degeneration 
during vascular remodeling. Mural cells are also important for 
maintaining vascular quiescence after vascular development is complete. 
4. ROLE OF ASTROCYTES 
Astrocytes are only observed in regions where vascularisation 
occurs. For example, astrocytes do not develop in the macula, which also 
remains avascular.  Astrocytes secrete VEGF, which the endothelial cells 
respond to through VEGF receptors on the endothelial cell surface. 
Astrocytes also play a critical role during guidance and maintenance of 
the neovascular plexus. As the vasculature matures, astrocytes begin to 
wrap around the newly formed vessels and this vessel-astrocyte 
association remains as an important aspect of the blood-retinal barrier 
throughout the adult life. 
5. DEVELOPMENT OF THE DEEP RETINAL VASCULAR 
PLEXUSES 
As the retina continues to expand, the vascular branches sprout 
perpendicular to the superficial plexus and dive towards the outer edge of 
the inner nuclear layer where they anastomose laterally and form a planar 
micro vascular plexus. General consensus is that the deep and 
intermediate plexuses form solely by the process of angiogenesis. 
Mechanisms involving specific expression of growth factors and cell-cell 
adhesion molecules are also important for initiation and guidance of the 
deep retinal vascular plexuses. 
6. VASCULAR MATURATION 
This involves appropriate mural cell recruitment and remodeling of 
the vascular plexus. Mural cell recruitment occurs almost concomitantly 
with neovascular formation. As the new vessels grow, endothelial cells 
secrete platelet derived growth factor (PDGF). Mural cells respond to this 
signal through receptors on their cell surface and are thereby recruited to 
the neo vessel surface. 
RETINAL ANGIOGENESIS AND GROWTH FACTORS 
1. VASCULOGENESIS 
Vasculogenesis in the embryo is different from that after birth. In 
the embryo, mesoderm-derived endothelial precursor cells give rise to the 
first embryonic blood vessels. The endothelial progenitors give rise to a 
primitive vascular labyrinth of arteries and veins. During subsequent 
angiogenesis the network expands, pericytes and smooth muscle cells 
cover nascent endothelial channels and a stereotypically organized 
vascular network emerges. 
Whereas in adults the bone marrow progenitor cells are recruited 
and incorporated in to nascent vessels or stimulate new vessel growth by 
releasing pro angiogenic factors an inducing the proliferation of resident 
endothelial cells. 
2. ANGIOGENESIS 
After vasculogenesis the nascent primitive vascular labyrinth 
expands and become remodeled in to a more complex network of larger 
vessels ramifying in to smaller vessels. 
This process includes, release of angiogenic cues that diffuse into 
the near by tissues and activate endothelial cells to induce endothelial cell 
matrix degradation. Endothelial cells then proliferate to navigate toward 
these cues and form a sprout, endothelial progenitor cells are also 
recruited from blood circulation to participate in the formation of new 
blood vessels 
3. ARTERIOGENESIS 
The establishment of functional vascular network requires the 
nascent vessels- formed by vasculogenesis and angiogenesis- mature in to 
durable, stable, non leaky and functional vessels. This stabilization 
requires recruitment of mural peri endothelial and smooth muscle cells, 
generation of an extra cellular matrix and specialization of vessel wall for 
structural support and regulation of vessel function- a process termed 
arteriogenesis. 
VASCULAR ENDOTHELIAL GROWTH FACTORS 
1. VEGF regulation and receptors 
Vascular endothelial growth factor (VEGF), or vascular 
permeability factor (VPF) is a 48 kDa homodynamic glycoprotein that 
functions as an endothelial cell- specific mitogen and vaso permeability 
factor. It is activated by hypoxia, high glucose, protein kinase C 
activation, advanced glycation end products, reactive oxygen species, 
activated oncogenes and a variety of cytokines. 
Activation of VEGF induces endothelial cell proliferation, induces 
vascular permeability, promotes cell migration and inhibits apoptosis 
The VEGF molecular family consists of five members 
1. Placental growth factor(PlGF) 
2. VEGF A 
3. VEGF B 
4. VEGF C 
5. VEGF D 
There are at least 6 known major isoforms of VEGF that arise from 
alternate splicing of the mRNA of a single gene: VEGF121, VEGF145, 
VEGF165, VEGF183, VEGF189, and VEGF206. VEGF165 is the predominant 
pathologic isoform. VEGF can be inhibited by blocking its production or 
receptors or the molecule itself in the extra cellular space. 
 
2. VEGF and systemic diseases 
VEGF stimulated collateral blood vessel formation helps to 
preserve myocardial function during coronary arterial occlusion. Several 
observations including the fact that direct VEGF gene transfer therapies 
have proved to be effective in coronary heart disease as well as peripheral 
vascular disease suggest that VEGF plays a significant role in this 
adaptive process. Thus although anti VEGF therapies appear promising as 
a means of reducing neo vascular complications from ischemic ocular 
diseases , they also have the potential to decrease collateral vascular 
formation and there by increase macro vascular complications associated 
with myocardial infarction and peripheral limb ischemia. 
3. VEGF and retinal vascular disease 
Levels of ocular VEGF are tightly correlated with both growth and 
permeability of new vessels. In patients with proliferative diabetic 
retinopathy in which tissue hypoxia promotes neovascularization, levels 
of VEGF are elevated in ocular tissues. These elevated levels of VEGF 
decline when treatment with pan retinal laser photocoagulation induces 
regression of neovascularization. 
Severe hypertension itself can induce a retinopathy characterized 
by increased retinal vascular leakage. The mechanism is increasing cyclic 
stretch in vascular walls, an action that may also involve the enhancement 
of angiotensin actions. 
Patients with both branch and central retinal vascular occlusions 
are at risk for development of retinal neovascularization. Increased VEGF 
levels are also correlated with the onset and persistence of 
neovascularization of the iris in cases of ischemic CRVO, and with 
increasing vascular permeability and severity of macular edema in cases 
of BRVO. 
RATIONALE FOR ANGIOGENESIS INHIBITORS IN 
RETINAL DISEASES 
The introduction of VEGF as a potential target in AMD came from 
examination of excised CNV membranes and autopsy specimens.  These 
studies showed that retinal pigment epithelial cells removed with the 
CNV membranes over expressed VEGF. Similarly, Frank and colleagues 
found high levels of VEGF in excised AMD-related CNV membranes. 
The presence of VEGF has been reported in CNV regardless of the 
fluorescein angiographic lesion subtype. Animal studies have also 
supported the role of VEGF in the pathogenesis of AMD. Indeed, the 
injection of a sub retinal recombinant adenovirus vector expressing 
VEGF in rats led to new blood vessel growth from the choriocapillaris, 
formation of breaks in Bruch's membrane, and CNV formation in the sub 
retinal space. 
 VEGF in human ocular fluids 
The growth of neovascular vessels in response to retinal ischemia 
("factor X") was initially proposed by Michaelson almost a half century 
ago. More recently, retinal hypoxia, which has been implicated in the 
pathogenesis of diabetic macular oedema, was shown to cause increased 
expression of VEGF. Indeed, evidence suggests that VEGF is a major 
mediator of diabetic retinopathy and diabetic macular oedema (DME). In 
1994, Aiello and colleagues demonstrated high levels of VEGF in ocular 
fluid of patients with diabetic retinopathy and other vascular retinal 
disorders. Further work by Aiello found that suppression of retinal 
neovascularization was achievable in vivo by inhibition of VEGF using 
soluble VEGF-receptor chimeric proteins. 
1. VEGF Inhibition in Age-Related Macular Degeneration 
VEGF inhibitors injected into the vitreous cavity have 
revolutionized treatment of AMD. In December 2004, pegaptanib sodium 
became the first anti-VEGF agent approved by the United States Food 
and Drug Administration (FDA) for treatment of all neovascular AMD, 
regardless of lesion composition. 
Pegaptanib is a pegylated aptamer that consists of an RNA 
oligonucleotide ligand that binds human VEGF165 with high affinity and 
specificity. Pegaptanib does not block the other isoforms of VEGF.   
Bevacizumab is a full-length, recombinant, humanized, 
monoclonal antibody directed against all VEGF isoforms. It was the first 
anti-VEGF agent approved by the FDA for systemic administration in 
treatment of colorectal cancer. Unfortunately, systemic effects, such as 
elevation of systolic blood pressure and the potential for systemic 
thromboembolic events, were concerns in the cancer studies, and 
although the first case using systemic bevacizumab for AMD held 
promise, the potential for adverse effects was deemed risky. In the 
summer of 2005, Rosenfeld pioneered the use of intravitreal fractionated 
dose of bevacizumab for retinopathy and AMD with impressive results. 
Since then, case series using intravitreal bevacizumab have shown good 
short-term efficacy (improved visual acuity and decrease of retinal 
thickness on ocular computed tomography [OCT]) with no obvious safety 
issues. 
Ranibizumab is a fragment of a humanized monoclonal antibody 
directed toward all isoforms of VEGF-A. It has a molecular weight of 48 
kD and is produced by an E. coli-expression system. Its unique structure 
was specifically engineered for ocular disease: Ranibizumab is made up 
of just the Fab fragment that was the basis for the full-length antibody, 
bevacizumab, and has been affinity-matured to have a higher binding 
affinity for VEGF than bevacizumab has. Eliminating the Fc portion 
results in less antigenicity and greater retinal penetration because of the 
smaller molecule size. The binding of ranibizumab to all isoforms of 
VEGF-A prevents dimerization with the VEGF receptors on cell surfaces 
(VEGFR1 and VEGFR2), thus reducing vascular leakage, angiogenesis, 
and endothelial cell proliferation. 
Both ranibizumab and bevacizumab block all forms of VEGF. 
Nevertheless, they have distinct differences that offer each advantages 
over the other. One advantage of ranibizumab is that it lacks the Fc region 
of the antibody, making it less likely to cause complement-mediated 
inflammation after injection. Ranibizumab has only 1 binding site for 
VEGF while bevacizumab has 2. 
In terms of clinical evidence, ranibizumab has the advantage over 
bevacizumab because it has been studied in placebo-controlled, phase 3 
trials, which led to its approval for the treatment of AMD by the US FDA 
in June 2006.  
In both the MARINA and ANCHOR studies, patients received 
monthly ranibizumab injections for 24 months. However, a monthly 
schedule in the real world is not particularly feasible because of both cost 
and time concerns. As such, research is ongoing to determine the best 
treatment protocol for ranibizumab. 
At this time, the primary issues surrounding the use of ranibizumab 
appear to be dosing, cost, and frequency of injection. Recently, however, 
the question of adverse effects was raised. Although ranibizumab has had 
a good safety profile in the phase 3 trials (the most common side effects 
are generally conjunctival haemorrhage, eye pain, and vitreous floaters), 
the manufacturer issued a warning of the possibility of increased risk for 
stroke. This warning was based on an interim analysis of the SAILOR 
trial, a phase 3b trial of 5000 patients that is studying 3 monthly 
injections followed by as-needed dosing. The final results from SAILOR 
will be awaited, both for the safety concerns as well as for the 
information it can provide about optimal dosing. 
Preliminary research into other types of anti-VEGF therapy is also 
ongoing. The most promising may be the VEGF trap -- a soluble protein 
that acts as a decoy VEGF receptor. It appears to bind VEGF-A with 
higher affinity than the other anti-VEGFs and can penetrate all retinal 
layers because of its small size.  RNA interference, which seeks to inhibit 
production of VEGF, is also under study, although the recent results of a 
phase 2 trial of bevasiranib, a small interfering (si)RNA, were 
disappointing. Still, other siRNA agents are being evaluated, as are 
tyrosine kinase inhibitors, which target the activation of VEGF receptors 
and downstream pathways. Whether these new approaches prove to be 
more efficacious than existing options awaits further research, as does the 
determination of optimal therapeutic approaches. It may well be that 
these types of drugs work best in synergy or that practitioners gain a new 
armamentarium of drug options. Certainly, randomized, placebo-
controlled, phase 3 trials will be needed to fully explore both existing and 
future treatment possibilities. 
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2. VEGF Inhibition for Diabetic Retinopathy and Diabetic 
Macular Oedema 
The success of anti-VEGF therapy in AMD has led researchers 
naturally to diabetic retinopathy and its leading cause of visual loss, 
DME. Although laser photocoagulation is still considered the standard of 
care for DME, there are instances when it is inappropriate or when it does 
not work; as a result, practitioners need reliable alternatives.   
Pegaptanib has been studied in DME with promising results. A 
placebo-controlled phase 2 trial randomized 172 patients with DME 
involving the center of the macula to intravitreal pegaptanib (0.3 mg, 1 
mg, 3 mg) or sham injections at study entry, week 6, and week 12. 
Additional injections and/or focal photocoagulation as needed were given 
for another 18 weeks. Median visual acuity improved and mean central 
retinal thickness decreased in the pegaptanib group compared with the 
sham group. In addition, fewer pegaptanib patients needed 
photocoagulation. 
A 12-month study of 15 patients with refractory DME showed 
improvements in visual acuity, foveal thickness, and macular volume. 
Finally, the pilot READ study was mounted to establish the safety of 
ranibizumab in DME. No systemic or ocular toxicities were noted in the 
phase 1 study. Moreover, visual acuity improved by 12 letters at 12 
months, and a significant reduction in mean retinal thickness was noted at 
7 months. The larger READ 2 study is currently enrolling patients and 
will examine the benefits of ranibizumab with laser photocoagulation vs 
ranibizumab vs laser photocoagulation alone. 
As with ranibizumab, bevacizumab has provided researchers with 
potential new avenues of treatment. Recent large case series indicate that 
it can be beneficial for DME, providing stability or improvement in visual 
acuity, OCT, and fluorescein angiography. The Pan American 
Ophthalmology Collaborative Groups reported 6-month results for 
patients with DME receiving at least 1 intravitreal injection of 1.25 mg or 
2.5 mg bevacizumab. Final best corrected visual acuity (BCVA) analysis 
by subgroups demonstrated that 32 (41.1%) eyes remained stable, 43 
(55.1%) improved 2 or more ETDRS lines of BCVA, and 3 (3.8%) 
decreased 2 or more ETDRS lines of BCVA. No ocular or systemic 
adverse events were observed. More substantial results should be 
forthcoming now that the DRCR.net has completed recruitment for a 
large study to assess the safety and efficacy of intravitreal bevacizumab 
for DME. 
Bevacizumab is also being tried for neovascular complications of 
proliferative diabetic retinopathy. Avery and colleagues conducted a 
retrospective, interventional, consecutive case series of 45 eyes in 32 
patients with retinal and/or iris neovascularization secondary to diabetes 
mellitus treated with intravitreal bevacizumab (6.2 micrograms-1.25 mg). 
No significant ocular or systemic adverse events were observed. 
Complete resolution of angiographic leakage of neovascularization of the 
disc was noted in 19 of 26 (73%) eyes, and leakage of iris 
neovascularization completely resolved in 9 of 11 (82%) eyes. Leakage 
was noted to diminish as early as 24 hours after injection. Short-term 
results suggested that intravitreal bevacizumab was well tolerated and 
associated with rapid regression of retinal and iris neovascularization 
secondary to proliferative diabetic retinopathy even with the lowest dose 
(6.2 micrograms) tested. However, observation of a possible therapeutic 
effect in the fellow eye raises concern that systemic side effects are 
possible in patients being treated with intravitreal bevacizumab (1.25 
mg). Lower doses may achieve a therapeutic result with less risk for 
systemic side effects. 
In general, these studies of pegaptanib, ranibizumab, and 
bevacizumab suggest that anti-VEGF therapy may have a role in DME 
and diabetic retinopathy.  
         At ARVO 2007, results from the first study investigating the 
efficacy of VEGF trap for DME were reported. The pilot study 
demonstrated significant reductions in central retinal thickness and 
improved acuity with treatment. In this study of 5 patients, 4 patients had 
visual improvement between 6 and 10 letters. Future trials were planned 
based on these impressive results. 
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3. VEGF Inhibition for CNV in Causes Other than AMD 
Because the most common cause of CNV is AMD, most FDA-
approved treatments for CNV are for CNV secondary to AMD. There is 
therefore an unmet clinical need for treatment of patients with CNV 
secondary to other causes -- which include myopic macular degeneration, 
presumed ocular histoplasmosis syndrome, angioid streaks, inflammatory 
retinal diseases, and idiopathic membranes. The only FDA-approved 
treatment for some of these diseases is PDT/verteporfin. However, as in 
CNV secondary to AMD, PDT/verteporfin can help stabilize but not 
restore vision. It is assumed that anti-VEGF therapy will have a role in 
CNV secondary to other causes as in AMD, although the published 
literature thus far consists only of case reports and nonrandomized case 
series. 
The first published treatment with anti-VEGF agents for non-AMD 
CNV was reported by Bennett and colleagues. In this case report, a single 
patient was treated with intravitreal pegaptanib for myopic degeneration 
and CNV with impressive results. Since this initial report, many newer 
agents have been investigated, such as ranibizumab and bevacizumab, 
and numerous reports were presented at the 2007 ARVO meeting. 
         Blinder and colleagues reported on the use of intravitreal 1.25-mg 
bevacizumab in 28 eyes of 28 individuals with CNV due to ocular 
histoplasmosis syndrome. In this retrospective chart review, the average 
pre-treatment visual acuity improved from 20 of 88 to 20 of 54 after 
almost 22 weeks of follow-up and an average of 1.8 injections per patient. 
A total of 71% of the patients studied had increased visual acuity.  
These preliminary results suggest that the anti-VEGF agents may, 
as with CNV secondary to AMD, improve vision in CNV secondary to 
other causes. Again, however, such issues as dose, cost, frequency, and 
safety will need to be addressed. 
4. VEGF Inhibition for Branch Retinal Vein Occlusion and 
Central Retinal Vein Occlusion 
Existing treatment options for BRVO and CRVO are 
unsatisfactory, and the potential for VEGF inhibition to combat macular 
oedema is increasing the amount of research into anti-VEGFs for BRVO 
and CRVO. Bevacizumab is receiving most of the attention. 
Avery and colleagues published their experience on treatment of 
macular oedema secondary to BRVO in 2007. In their retrospective 
review of patients treated with intravitreal bevacizumab (1.25 mg), 27 
consecutive patients were evaluated. Mean visual acuity improved from 
20 of 200 at baseline to 20 of 100 at 3 months (P < .001). Similarly, the 
mean central subfield thickness decreased from 478 microns at baseline 
to 332 microns at last follow-up (P < .001). No adverse events -- 
including endophthalmitis, clinically evident inflammation, increased 
intraocular pressure, retinal tears, retinal detachment, or thromboembolic 
events -- were observed in any patient. 
Although several reports have noted visual improvement with use 
of bevacizumab, others have noted anatomic responses but not visual 
ones. For example, Fine and colleagues conducted a retrospective study 
of 16 eyes of 15 patients with macular oedema due to CRVO who 
received a mean 2.8 injections of bevacizumab. Although the mean 
central macular thickness improved, mean baseline acuity was 
unchanged. Similarly, several case series that were presented at ARVO 
on treatment of both BRVO and CRVO with bevacizumab showed 
anatomic responses but variable visual outcomes. In addition, results of 
some of the cases warn of the possibility of recurrent macular oedema 
(so-called rebound oedema) following bevacizumab treatment. In these 
instances, the recurrent macular oedema may be more severe than the 
original macular oedema. 
Research into the use of anti-VEGF agents in the treatment of 
CRVO and BRVO is in the preliminary stages. So far, it has focused on 
bevacizumab with mixed results. Clearly, larger, prospective studies will 
be needed to better determine the effects on visual outcome, as well as to 
establish treatment issues, such as safety and dose. 
 AN UPDATE ON BEVACIZUMAB 
Bevacizumab (Avastin, Genentech) is a full-length, humanized, 
murine  monclonal antibody directed against all the biologically active 
forms of vascular endothelial growth factor-A (VEGF). Bevacizumab, the 
first anti-VEGF drug to be approved by the Food and Drug 
Administration, was developed as an intravenous therapy for cancer 
patients because VEGF is one of the major angiogenic stimuli responsible 
for neovascularization in tumors. Anti-VEGF therapy has shown 
promising results in several forms of cancer, but the drug is currently 
approved only for the treatment of metastatic colorectal cancer. When 
used in cancer therapy, bevacizumab is infused at a dose of 5 mg/kg 
every two weeks until the patient dies or significant disease progression is 
observed. In clinical trials, the most common adverse event caused by be-
vacizumab was hypertension.  
Systemic Bevacizumab 
The role of VEGF in neovascular AMD has now been confirmed as 
the result of the Phase III clinical trial of the anti-VEGF drug pegaptanib 
sodium (Macugen, Eyetech). Pegaptanib sodium is now approved for the 
treatment of all neovascular AMD; however, the average pegaptanib-
treated patient still continues to lose vision while receiving therapy. 
Another anti-VEGF drug known as ranibizumab (Lucentis, Genentech) 
was shown to improve visual acuity, angiographic and optical coherence 
tomography outcomes in open-label, uncontrolled Phase I/II studies. 
Genentech’s one-year, Phase III results confirm earlier studies in AMD 
patients. Patients with predominantly occult macular neovascularization 
treated with ranibizumab had an overall vision improvement and 
statistically significant better outcomes than the sham-injected controls. 
The disadvantages of systemic therapy, however, include systemic 
exposure to an antiangiogenic drug at therapeutic levels, resulting in a 
higher risk of systemic adverse events compared to intravenous injection. 
SANA 
In the spring of 2004, Systemic Avastin for Neovascular AMD 
(SANA) study at the Bascom Palmer Eye Institute. In this study systemic 
bevacizumab was offered as salvage therapy for patients who were not 
candidates for verteporfin photodynamic therapy or who refused PDT. 
Pegaptanib sodium was not yet commercially available. Unlike the regi-
mens used in cancer therapy, treating patients only two or three times 
followed by a period of close observation was proposed, with retreatment 
possible if the leakage from the neovascularization recurred. Since this 
article was published, a total of 18 patients have been followed for at least 
24 weeks, and the 24-week results confirm and improve upon the pre-
liminary results observed at 12 weeks (submitted for publication). Of the 
18 patients, nine initially received three treatments, and 11 received only 
two treatments. The majority of patients did not require another treatment 
through 24 weeks. 
With improvement in visual acuity, OCT and angiographic 
outcomes, the systemic use of bevacizumab appeared to be both effective 
and durable. Moreover, the cost of intravenous bevacizumab therapy is 
comparable to the cost of pegaptanib therapy. The average drug cost for 
bevacizumab is $2,200 per infusion, and the cost for the 24 weeks of 
therapy is $4,400 for most patients, roughly equivalent to four intravitreal 
injections of pegaptanib over 24 weeks. 
Intravitreal Bevacizumab 
Bevacizumab was used as an intravitreal injection in humans in any 
of the early clinical studies. The preclinical data in primates suggested 
that intravitreal bevacizumab would be too large to penetrate the retina 
and result in any therapeutic effect, but bevacizumab was never tested in 
an animal model of macular neovascularization to see if this assumption 
was correct. Once we observed the dramatic results of systemic 
intravenous bevacizumab in patients with neovascular AMD, a much 
lower dose of bevacizumab injected into the eye could result in a similar 
benefit while reducing the risk of systemic adverse events. It has been 
calculated that a dose of about 1 to 1.5 mg of bevacizumab would be ap-
proximately 400-fold less than the systemic dose of bevacizumab used in 
the SANA study. 
Another appealing feature of intravitreal bevacizumab is its low 
cost. Compared with the cost of pegaptanib sodium, an intravitreal dose 
of bevacizumab would be a bargain. While a dose of pegaptanib (0.3 mg) 
is approximately $1,000 or $3,300 per mg, the proposed 1-mg dose of 
bevacizumab would cost $5.50. Moreover, a dose of 1 to 1.25 mg could 
be conveniently injected using 0.04 ml to 0.05 ml of the commercially 
supplied bevacizumab, which is not known to contain preservatives or 
additives that may be toxic to the retina. At the Bascom Palmer Eye 
Institute, off-label intravitreal bevacizumab was offered to patients as a 
salvage treatment for those who continue to lose vision associated with 
neovascular lesions and worsening OCT profiles despite treatment with 
approved therapies. In the first report of a patient receiving intravitreal 
bevacizumab, improvement in angiographic and OCT outcomes after one 
injection were observed, nearly identical to the outcomes that observed 
following systemic bevacizumab and intravitreal ranibizumab. The 
patient’s vision remained stable over four weeks, and this patient has 
remained stable through six months and has not required another 
injection. 
Since this first patient was injected, anecdotal experience with 
intravitreal bevacizumab has grown, and the positive outcomes were ob-
served in this first patient have been reliably reproduced in other patients. 
It is now obvious that a large, prospective clinical study must be initiated 
to determine the safety and efficacy of intravitreal bevacizumab. With an 
intravitreal half-life that may be twice as long as ranibizumab, we may be 
able to dose less frequently than ranibizumab, perhaps every eight weeks 
or 12 weeks. If intravitreal bevacizumab proves to be safe and effective 
for the treatment of neovascularization and macular edema from a wide 
range of ocular diseases, then intravitreal bevacizumab would have 
immediate global impact because of its low cost and worldwide 
availability. 
REVIEW OF LITERATURE 
• MARINA (Minimally Classic/Occult Trial of the Anti-
VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD). 
This Phase III multicenter, randomized, double-masked, sham injection-
controlled trial included 716 patients with minimally classic/occult CNV 
secondary to AMD. Eligible patients had not previously received 
subfoveal laser treatment, verteporfin (Visudyne) photodynamic therapy, 
or experimental treatments for their AMD in the study eye. Patients were 
randomized 1:1:1 to sham injection or to ranibizumab (0.3 mg or 0.5 mg) 
injected intravitreally monthly for 24 months. The primary efficacy 
endpoint is the proportion of subjects losing less than 15 ETDRS letters at 
one year. Approximately one-third of the patients had minimally classic 
CNV and two-thirds had occult CNV. Preliminary analysis of one-year 
MARINA data revealed that approximately 95 percent of patients treated 
with ranibizumab lost fewer than 15 letters at one year, compared to 
approximately 62 percent in the control group (p<.0001). On average, the 
patients treated with ranibizumab had a significant visual acuity 
improvement compared to baseline, while the control group experienced 
a substantial decrease from baseline in mean VA. Ocular adverse events 
were similar to those of earlier trials, and no increase in the serious non-
ocular adverse events relative to the control group was noted. The 
incidences of uveitis and endophthalmitis were each less than 1 percent. 
• FOCUS (RhuFab V2 Ocular Treatment Combining the Use 
of Visudyne to Evaluate Safety) is a randomized, single-masked, Phase 
I/II trial investigating safety, tolerability and efficacy of ranibizumab 0.5 
mg in combination with verteporfin PDT versus verteporfin PDT alone in 
patients with subfoveal predominantly classic CNV due to AMD. One 
week before the first administration of either intravitreal ranibizumab or 
sham injection to the study eye, patients are treated with verteporfin PDT, 
with as many as 23 additional monthly injections with ranibizumab or 
sham injection. Patients may continue to receive verteporfin PDT at the 
investigators’ discretion and in accord with product labeling. The primary 
efficacy endpoint is the proportion of subjects losing fewer than 15 letters 
of VA at one year. The study enrolled 162 patients. The study has met its 
primary endpoint based on one-year data: Approximately 90 percent of 
patients treated with the combination therapy had stable or improved vis-
ual acuity, compared with approximately 68 percent of patients in the 
control arm of PDT alone (p=.0003). Patients treated with combination 
therapy had significantly improved average VA compared to baseline; 
mean VA in the PDT-alone control group decreased from baseline. There 
was an increased risk of uveitis in combination therapy patients compared 
with those treated with PDT alone. The study protocol was amended after 
data safety monitoring identified this imbalance. Endophthalmitis was the 
next  most common ocular serious adverse event occurring in 
ranibizumab-treated patients. The frequency of cerebral vascular events 
was slightly higher in patients treated with ranibizumab, whereas 
myocardial infarctions were slightly more frequent in the PDT-alone arm; 
the differences between these groups was not statistically significant. 
• ANCHOR (Anti-VEGF Antibody for the Treatment of 
Predominantly Classic Choroidal Neovascularization in AMD) is a 
multicenter, randomized, double-masked, active-treatment controlled 
Phase III trial evaluating the safety and efficacy of ranibizumab in 423 
subjects with predominantly classic subfoveal CNV, with sites in the 
United States, Europe and Australia. Inclusion criteria were the same as 
those of the MARINA study. Patients in this trial are being randomized 
1:1:1 to either verteporfin PDT plus sham injection or to placebo PDT 
plus ranibizumab (0.3 mg or 0.5 mg) monthly for 24 months. Patients in 
the ANCHOR trial are being evaluated by fluorescein angiography every 
three months to determine the need for additional PDT or placebo PDT. 
The study is ongoing. 
INTRAVITREAL INJECTIONS–PROCEDURE 
GUIDELINES 
            Injection procedure guidelines include consideration of pre 
existing conditions such as active external infection, eyelid abnormalities, 
povidone iodine, lid scrubs, pre injection topical antibiotics, lid speculum, 
drape, gloves, and anaesthesia and post injection topical antibiotics.  
           In general the risk of endophthalmitis following intra vitreal 
injection is estimated to be approximately < 0.1%.  
Guidelines for intra vitreal injection: 
1. Povidone iodine for ocular surface, eyelid and eye lashes 
2. Use of speculum and avoid contamination of the needle with eye lid 
margin 
3. Avoid extensive massage of the eye lids either pre or post injection 
4. Dilate pupil 
5. Adequate use of anaesthetic (topical drops/ sub conjunctival 
injection) 
6. Avoid prophylactic or post injection paracentesis 
7. IOP to be checked following injection 
8. Dilated fundoscopic examination should be performed following 
injection to confirm central retinal artery perfusion and intra ocular 
location of the drug. 
Guidelines for follow up 
Patients should be followed up on the immediate day following 
intra vitreal injection. How ever patients should be instructed to contact 
ophthalmologist if there if increased ocular redness or discomfort or 
decreased vision compared to that present right after the injection 
procedure. 
AIM OF THE STUDY 
1. To evaluate the visual acuity responses following intravitreal 
injection of bevacizumab in case of  
a. Neo-vascular AMD 
b. Progressing neovascularization inspite of complete PRP in 
cases of  PDR 
c. NVD / NVE not responding to PRP in cases of Retinal vein 
occlusion. 
2. To evaluate the change in macular thickness by OCT following 
injection in above said conditions. 
3. To evaluate the angiographic changes following treatment. 
4. To evaluate the safety and efficacy of intravitreal injection of 
Bevacizumab.   
 
 
  
DESIGN 
Interventional, Prospective, Non-randomized clinical study. 
MATERIALS AND METHODS 
This study was done in Retina clinic- Regional Institute of 
Ophthalmology and Government Ophthalmic Hospital, Chennai during 
the period of June – 2008 to November 2008. 
INCLUSION CRITERIA: 
1. CNV attributable to AMD diagnosed by FFA and OCT with 
BCVA of less than 6/24. 
2.  PDR patients with disease progression despite complete PRP. 
3. CRVO patients with neovascularization not responding to laser 
photocoagulation. 
4. Ability to understand and sign consent form.  
EXCLUSION CRITERIA: 
1. Prior treatment for CNV. 
2. Patients with tractional retinal detachment in a case of high risk 
PDR. 
3. History of uveitis. 
4. History of vitrectomy. 
5. Patients with uncontrolled hypertension. 
6. Patients with recent myocardial infarction. 
7. Patients with recent cerebral vascular accident.  
PROCEDURE 
Patients who were referred to Retina clinic with provisional 
diagnosis of AMD, PDR, and CRVO were screened and selected for the 
study. 
         All the patients were taken a brief history, and subjected to detailed 
systemic and ophthalmic evaluation. 
         Anterior segment examination with Slit lamp biomicroscope and 
posterior segment examination using 90D, binocular indirect 
ophthalmoscope and a detailed fundus drawings were done and Fundus 
photograph was also taken for documentation. B-scan USG, Fundus 
fluorescein angiography and Optical coherence tomography were done 
for all the patients. 
Twenty eight eyes of 28 patients with neovascular AMD, four eyes 
of 4 patients with proliferative diabetic retinopathy with post laser status 
and two eyes of 2 patients with retinal vein occlusion were included. 
The off-label use of the drug and its potential risks and benefits 
were discussed extensively with all patients. All patients signed a 
comprehensive consent form before administration of the intravitreal 
bevacizumab. 
A commercially available bevacizumab (1.25mg/0.05ml)  was 
prepared for each patient and placed in a tuberculin syringe  using aseptic 
techniques. After the eye had been prepared in a standard fashion using 
5% povidone iodine and topical antibiotics, 1.25 mg (0.05 ml) of 
bevacizumab was injected intravitreally via the pars plana. After the 
injection, intraocular pressure and retinal artery perfusion were checked, 
and patients were instructed to administer topical antibiotics for 3 days. 
Patients were called 2 to 3 days after injection and were re examined 
within 1 week. 
Patients received reinjections on a monthly basis until macular 
edema, /or pigment epithelial detachment (PED) / or neovascularization 
resolved. 
MAIN OUTCOME MEASURES: 
• Best corrected visual acuity (Snellen’s chart) 
• Macular thickness by OCT ( SPECTRAL)  
• Changes in  Fluorescein angiogram patterns in the form of reduction 
in size of the lesion and decrease in leakage. 
 
WET AMD with Macular thickness of 432µ 
 
 
 
 
 
 
 
 
 
 
 REVIEW 
All the patients were asked for regular follow-up at 2weeks, 4 
weeks, 8weeks, 12weeks and 16weeks. At each visit patients were 
checked for intra-ocular pressure, BCVA,  were checked and Fundus 
photograph, FFA, and OCT were recorded. 
 
Occult CNV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATIONS AND RESULTS 
TABLE  1: AGE DISTRIBUTION 
Total no of patients—34 
Age distribution No of patients Percentage 
   30-40 yrs           4       12 
   40-50 yrs         13        38 
   50-60 yrs         17        50 
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In our study, most of the patients were in the age group of 50-60 
yrs which is about 50%. The upper age limit being 60yrs and lower age 
limit being 34. 
59%41%
 
TABLE 2: SEX DISTRIBUTION 
Sex No of patients Percentage 
     Male 
 
20 59 
     Female 
 
14 41 
 
 
 
 
 
 
Male: Female ratio ~~1.5: 1 
TABLE  3: INDICATIONS 
Total no. of patients – 34 
Indications 
 
No of patients Percentage(%)
 
Choroidal neovascularisation 28 82 
Proliferative diabetic retinopathy 4 12 
Retinal vein occlusion 2 6 
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           Though there are a lot of indications for intravitreal anti VEGF, we 
have considered only 3 conditions–Choroidal neovascularization, and as 
adjunct to photocoagulation in cases with proliferative diabetic 
retinopathy and retinal vein occlusion not responding to PRP. 
          Of these, we have taken about 82% cases with CNV. Both classic 
and occult CNV irrespective of the location were equally considered.  
TABLE – 4:  VISUAL ACUITY – Pre treatment  
 
TABLE – 4 A -in cases with CNV 
Visual acuity No.of patients Percentage 
  HM – 1/60 11 40 
  2/60 – 4/60 12 43 
  5/60 – 6/24 5 17 
 
 
TABLE – 4 B – cases with PDR 
Visual acuity No.of patients Percentage 
  HM – 1/60            3          75 
  2/60 – 4/60            1          25 
  5/60 – 6/24            -           -- 
 
TABLE – 4 C – cases with  CRVO 
Visual acuity No.of patients Percentage 
 HM – 1/60           2          100 
 2/60 – 4/60           -             - 
 5/60 – 6/24           -              - 
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Most of the patients in our study, were having V/A of less than 
1/60. 43% of CNV patients were having V/A of between 2/60 – 4/60.  
The least V/A of these is a patient of CNV with 6/24. 
TABLE –5: Angiographic classification in CNV 
Angiographic types No.of patients Percentage 
Classic CNV            20          71 
Occult CNV             8          29 
 
OCCULT
CLASSIC
 
In our study 71% of patients were with classical angiographic type 
with CNV. 
TABLE – 6 
TABLE – 6 A: Macular thickness in CNV – Pre- injection 
No.of cases Macular thickness 
Classic Occult 
Percentage 
100-150µ        --   --         -- 
150-200µ       1   2          11 
200-250µ       3   3          21 
250-350µ      10   2          43 
More than 350µ 
 
      6 
 
  1 
 
         25 
 
About 43% of patients were with macular thickness between 250 - 
350µ and there were no patients with macular thickness less than 150µ. 
TABLE – 6 B: Macular thickness in PDR  
Macular thickness No.of cases Percentage 
100-150µ 1 25 
150-200µ 1 25 
200-250µ 1 25 
250-350µ -- - 
More than 350µ 1 25 
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Macular thickness in CNV—Pre injection 
TABLE – 6 C: Macular thickness in RVO 
Macular thickness RVO Percentage 
 
100-150µ -- -- 
150-200µ -- -- 
200-250µ 2 100 
250-350µ -- -- 
More than 350µ 
 
-- -- 
 
 
Both the patients of CRVO were with macular thickness ranging 
between 200 - 250µ. 
Macular thickness in PDR and CRVO- Pre injection 
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TABLE – 7 
TABLE 7 A: Improvement in V/A–post injection in cases of classic 
CNV 
CLASSIC CNV Lines of 
improvement in 
visual acuity At 
2wks 
At 
4wks 
At 
2months
At 
3months 
At 
4months
No change 19 6 2 1 1 
1 line 1 9 13 9 7 
2 lines -- 5 6 9 12 
More than 2 lines -- -- 1 1 1 
 
Most of the cases showed no change in visual acuity in 2 weeks, 
but about 35% cases with classic CNV showed 1 line improvement, and 
60% of cases showing 2lines improvement at the end of 4 months which 
correlates with Rich RM, Rosenfeld – et-all  Retina ; 26:495-511. 1 
patient showed no improvement because of macular scarring. 
 
 
 
 
 
 
Improvement in V/A- post injection in  classic CNV 
   (at 4 months). 
 
 
 
 
 
 
 
 
 
 
 
Improvement in V/A- post injection in occult CNV  
(at 4 months) 
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TABLE–7 B Improvement in V/A–post injection in cases of occult 
CNV 
OCCULT CNV Lines of 
improvement in 
V/A At 
2wks 
At 
4wks 
At 
2months 
At 
3months 
At 
4months 
 No change 7 3 2 1 -- 
 1 line 1 4 2 3 2 
 2 lines -- 1 2 2 4 
More than 2 lines -- -- 2 2 2 
 
About 25% of occult CNV cases showing 2 line improvement at 4 
weeks and 50% showed more than 2 line improvement at 4 months which 
is in par with Geitzenauer W – et-all, Klin Monatsbl Augenheilkd 2006; 
223:822-7. 
TABLE – 7 C: Improvement in V/A – Post injection in cases with 
PDR 
PDR Lines of 
improvement in 
v/a At 
2wks 
At 
4wks 
At 
2months
At 
3months 
At 
4months 
No change      4     2      1       1      2 
1 line      --     2      2       3      2 
2 lines     --     --      1       --      -- 
More than 2 lines     --     --      --       --      -- 
 
In cases with PDR, out of 4 patients, 3 showed 1 line improvement 
at the end of 3 months, but 1 dropped V/A because of macular oedema 
caused by new vessels elsewhere and he underwent repeat injection 
which goes with the study of Quiroz – Mercado H et - all Semin 
Ophthalmol ; 22:109-25. 
 
 
 
 
Improvement in V/A – Post injection in cases with PDR 
(at  4 months) 
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TABLE – 7 – D: Improvement of V/A – Post injection in cases with 
RVO 
retinal vein occlusion Lines of 
improvement in 
V/A At 
2wks 
At 
4wks 
At 
2months
At 
3months 
At 
4months 
No change    2    1      1      1      1 
1 line     --    1     1     1     1 
2 lines     --     --      --      --     -- 
More than 2 lines      --     --      --      --      -- 
 
Only 2 patients of CRVO were selected, who were not responding 
to pan retinal photocoagulation of 3 sittings. Of  these 1 showed 1 line 
improvement at the end of 4 months which supports the study of Lynch 
SS, Cheng CM Ann Pharmacother 2007; 41:614-25 and 1 showed nil 
improvement because of glaucomatous optic atrophy. 
 
 
 
 
 
 
 
 
Improvement in V/A – Post injection in cases with CRVO 
(at  4 months) 
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TABLE – 8 
TABLE – 8 A: REDUCTION IN MACULAR THICKNESS in CNV 
–Classic type  (Post-injection) 
CLASSIC CNV Reduction In Retinal 
Thickness 
2 wks 4 wks 2m 3m 4m 
 UPTO 50µ 15 14 12 9 4 
   51-100µ 2 3 5 6 10 
   101-150µ -- -- 1 3 4 
   151-200µ -- -- -- 1 1 
MORE THAN 200µ -- -- -- -- -- 
NO CHANGE 3 3 2 1 1 
 
TABLE – 8 B 
OCCULT  CNV  Reduction in retinal 
thickness 
2 wks 4 wks 2m 3m 4m 
 UPTO 50µ 5 4 3 2 1 
   51-100µ 2 3 4 4 3 
   101-150µ -- -- 1 1 3 
   151-200µ -- -- -- 1 1 
MORE THAN 200µ -- -- -- -- -- 
NO CHANGE 1 1 -- -- -- 
 
     About 73% of Classic CNV and 50% of Occult CNV   showed 
reduction in macular thickness of 50µ at the end of 1month, and 50% of 
both CNV types showed reduction of 100µ at the end of 4months which 
correlates well with the study of Moschos MM – et-all Doc Ophthalmol 
2007; 114:37-44. 1 patient showed no improvement and he was found to 
have CNVM with scar formation. 
Reduction in macular thickness (µ) in classic CNV-Post 
injection at 4 months 
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Reduction in macular thickness (µ) in occult CNV-Post 
injection at 4 months 
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TABLE – 8 C: Reduction of macular thickness in PDR cases 
PDR Reduction In Macular 
Thickness 
2 wks 4 wks 2m 3m 4m 
 UPTO 50µ 1 2 1 1 1 
   51-100µ -- -- 1 2 2 
   101-150µ -- -- -- -- -- 
   151-200µ -- -- -- -- -- 
MORE THAN 200µ -- -- -- -- -- 
NO CHANGE 3 2 2 1 1 
 
In cases with PDR, 50% showed improvement of 50µ reduction at 
the end of 1month post injection, 50% showed reduction of upto 100µ at 
the end of 4 months and 1 patient showed no change because of non-
resolving cystoid macular oedema associated with vitreo-macular 
traction. 
 
 
 
 
Reduction in macular thickness (µ) in PDR-Post injection at 
4 months 
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TABLE – 8 D: Reduction of macular thickness in CRVO cases 
CRVO Reduction In 
Macular Thickness 
2 wks 4 wks 2m 3m 4m 
 Upto 50µ -- -- 1 2 2 
   51-100µ -- -- -- -- -- 
   101-150µ -- -- -- -- -- 
   151-200µ -- -- -- -- -- 
More than 200µ -- -- -- -- -- 
No change 2 2 1 -- -- 
 
In cases with CRVO, all the 2 showed improvement of 50µ 
reduction retinal thickness at the end of 4 months because of vascular 
perfusion factor associated with Anti VEGF which correlates with the 
study of Schaal KB et-all; ophthalmology 2007; 104; 285-9. 
 
 
 
 
Reduction in macular thickness (µ) in CRVO cases-Post 
injection at 4 months 
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TABLE – 9: ANGIOGRAPHIC PATTERNS 
TABLE – 9 A  Post injection in cases with CNV: 
No of cases with leakage  Disease 
conditions 
At 2wks At 4 wks At 2 
months 
At 
3months 
at 
4months 
Classic CNV      14      9     7      3       1 
Occult CNV       5      3      3      2      -- 
  
At the end of 4 weeks, 50% of both occult and classic types 
showed leakage and at the end of 4 months no cases of occult CNV 
showed leakage which supports the study of  Aiesenbrey et-all Graefes 
Arch Clin Exp Ophthalmol 2007; 245:941-8. 1 patient of classic CNV 
showed leakage with staining at the end of 4 months because of macular 
scarring. 
TABLE – 9 B 
Disease No of cases with leakage 
Conditions At 2 
wks 
At  
4 wks 
At 
2months 
At 
3months 
At 
4months 
          PDR        4       3      2       2      2 
        CRVO        1       1      --      --       -- 
 
All the cases of PDR showed leakage from NVE at the end of 
1month, and 50% of them still showed leakage at the end of the study and 
25% 0f them underwent repeat injection with fillin PRP. This leakage is 
attributable to uncontrolled diabetic status. 
Out of 2 patients of CRVO, 1 showed leakage at the end of 
2months and he stopped leakage at the end of 4 months. 
 
 
 
 
 
ANGIOGRPAHIC PATTERNS AT 4 MONTHS 
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DISCUSSION 
• This is a 6month prospective, non-randomized clinical study 
to investigate the safety and efficacy of intravitreal 
bevacizumab for the treatment of neovascular AMD, and as 
an adjunct to PDR and CRVO cases with progressing 
neovascularization inspite of complete PRP. 
• The main aim was to evaluate the improvement in V/A, 
decrease in macular thickness and qualitative decrease in 
angiographic leakage in the above said conditions following 
intravitreal injection. 
• Of the 34 patients who met the inclusion criteria for the study, 
20 were male  and 14 were female, the ratio being 1.5:1. The 
mean age was 55 years. 
• Out of 34 eyes, 82% of cases were with CNV, of which 71% 
were with Classic type and 29% with Occult type of CNV. 
Out of 18% of the remaining, PDR cases constitutes about 
12% and CRVO cases constitutes about 6%. 
• The mean baseline pre-procedure V/A considered was 3/60, 
the least V/A being HM , and the highest V/A being 6/24. The 
baseline mean macular thickness was 356µ. 
•  All the patients were given 1.25mg of Bevacizumab 
intravitreally under aseptic precautions after explaining the 
procedure who then signed a consent form. Follow-up ranged 
from 2 to 16 weeks. All 34 patients completed a 16-week 
follow-up visit. 
• During each follow-up, patients were checked for 
improvement in V/A, decrease in macular thickness and 
change in angiographic patterns. Fundus photographs were 
taken for documentation. 
VISUAL ACUITY: (Snellen’s Chart) 
• The effect of intravitreal bevacizumab seems to be similar 
between both Classic and Occult CNV. Generally, there was a 
significant improvement in V/A by 4weeks of about 50% and 
by the end of 4 months, 60% of Classic CNV and 50% of 
Occult CNV showed 2 lines of improvement by Snellen’s. 
25% of both types showed more than 2 lines of improvement 
by the end of the study. 1 case of Classic CNV showed no 
improvement because of macular scarring. 
•   The response of Bevacizumab to Proliferative diabetic 
retinopathy is less when compared to other conditions because 
of associated systemic factors. The mean V/A improves by 
50% (1 line improvement) by the end of 4weeks which 
remained the same by the end of the study in 50% of cases. 1 
case dropped V/A after 3rd month because of cystoid macular 
oedema with vitreo-macular traction and he underwent repeat 
injection. 
• Out of 2 cases of CRVO, 1 case (50%) started showing 1 line 
improvement by 4th week and he maintained  it till the end of 
the study, 1case showed no improvement because of optic 
atrophy. 
• Unlike BCVA, the lesion size by fundus appearance did not 
show the same rapid improvement. This is because, VEGF is 
necessary for the growth of immature blood vessels but 
established blood vessels may not require VEGF and this may 
explain the less dramatic response of the clinical appearance 
of the lesion when compared with V/A. 
• This study shows that the vast majority of patients 
demonstrated stability or improvement of the VA. Of those 
few patients with a visual decline, the change was felt to be 
due to disease progression rather than drug toxicity. 
MACULAR THICKNESS: (Stratus OCT) 
• The base line mean macular thickness in CNV cases was 345µ 
About 73% of Classic CNV and 50% of Occult CNV   showed 
reduction in macular thickness of 50µ at the end of 1month, and 
50% of both CNV types showed reduction of 100µ at the end of 
4months. 1 case of Classic CNV showed no improvement till 
the end of the study because of macular scarring. 
• In PDR cases, 50% (2cases) showed improvement of 50µ 
reduction at the end of 1month post injection, 50% showed 
reduction of upto 100µ at the end of 4 months and 25% (1case) 
showed no change because of non-resolving cystoid macular 
oedema associated with vitreo-macular traction.  
•  In CRVO, out of 2 cases, 1case showed reduction of macular 
thickness by the end of 2 months, both showed 50% reduction 
by the end of the study and this is because of vascular perfusion 
factor associated with Anti VEGF Bevacizumab. 
• Thus the qualitative assessment of the OCT showed marked 
reduction in subretinal fluid and cystic oedema 1month after 
injection. The earliest sign of reduction was the disappearance 
of SRF. Although PEDs were noted to decrease in elevation in 
most patients, quantitative evaluation of this change could not 
be obtained with the current OCT software, which measures the 
distance between the retinal pigment epithelial layer and the 
ILM and, thus, does not include the PED thickness in the 
calculations. 
ANGIOGRAPHIC PATTERNS 
• At the end of 4 weeks, 50% of both occult and classic types 
showed leakage and at the end of 4 months no cases of occult 
CNV showed leakage which supports the study of  Aiesenbrey 
et-all Graefes Arch Clin Exp Ophthalmol 2007; 245:941-8. 1 
patient of classic CNV showed leakage with staining at the end 
of 4 months because of macular scarring. 
 
• All the cases of PDR showed leakage from NVE at the end of 
1month, and 50% of them still showed leakage at the end of the 
study and 25% 0f them underwent repeat injection with fillin 
PRP. 
•  Out of 2 patients of CRVO, 1 showed leakage at the end of 
2months and he stopped leakage at the end of 4 months.  
• We identified no cases of uveitis, endophthalmitis, ocular 
toxicity, hypertension, or thromboembolic events after injection, 
a finding consistent with that of other investigators (Rosenfeld 
P. Changing strategies in the management of neovascular age-
related macular degeneration. Presented at: Retina Society 
Meeting, September, 2005; San Diego, California).  
The use of intravitreal bevacizumab is appealing for a number of reasons 
First, the MARINA (Minimally Classic/ Occult Trial of the Anti-
VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD) 
results demonstrated, for the first time, an average improvement in VA 
with intravitreal ranibizumab treatment for neovascular AMD [Miller JW. 
Randomized, controlled phase III study of ranibizumab (Lucentis) for 
minimally classic or occult neovascular age-related macular degeneration. 
Paper presented at: ASRS meeting, July 18, 2005; Montreal, Canada]. 
This has raised physician and patient expectations. Ranibizumab is not 
Food and Drug Administration approved and, to date, has been denied 
fast-track approval status. However, bevacizumab is Food and Drug 
Administration approved for colorectal cancer and, therefore, is available 
for use on an off-label basis. Given its molecular similarity to 
ranibizumab, one reasonably could expect similar results if it penetrates 
the retina. 
Second, the half-life of intravitreal bevacizumab is expected to be 
about twice that of ranibizumab, and if, indeed, these preliminary data are 
confirmed by a prospective trial, and bevacizumab is found to be 
effective in sequestering VEGF and improving the outcome of patients 
with AMD, then less frequent administration than with ranibizumab may 
be required. 
Third, the cost per dose of intravitreal bevacizumab is significantly 
less than that of pegaptanib or the anticipated cost of ranibizumab. Hence, 
the potential cost savings for the United States health care system could 
be substantial, and the treatment may be available worldwide to patients 
who may not be able to afford the more expensive alternatives. 
The optimum dosing sequence for intravitreal bevacizumab is 
undetermined. We elected to defer reinjection into eyes when there was 
complete resolution of SRF, macular edema, and PEDs until there was a 
recurrence. Some patients have not recurred 15 weeks after a single 
injection. Those cases that did recur after initially resolving  responded to 
repeat injections without loss of vision—a finding similar to what 
Michels et al reported in the systemic bevacizumab trial. It is possible 
that a different dosing schedule, such as a series of monthly injections for 
an extended period followed by retreatment for recurrences, may be 
superior to the method used in this study; however, we chose to err on the 
side of undertreatment until further toxicity data are obtained. 
SUMMARY 
A total of 34 Patients were included in this study. 
Age group was between 30-60 years. 
All the patients were examined for V/A, FFA for leakage, and OCT 
for macular thickness before and at 2wks, 4wks, 2, 3, and 4months after 
intravitreal injection. 
1 out of 4 PDR patients was given repeat injection at the end of 3rd 
month as there was no response for single injection. Overall 70% of CNV 
cases (both classic & occult) responded with improvement and 
stabilization of V/A of upto 2 lines, where as only 50% of PDR and 
CRVO cases responded with 1line improvement by the end of the study. 
78% of CNV cases irrespective of types and 50% of PDR cases 
responded with reduction of macular thickness of upto 100µ whereas 
both cases of CRVO cases responded with reduction of 50µ by the end of 
the study. 
Almost all the cases of CNV and CRVO responded to treatment 
with no leakage in angiography whereas 50% of PDR cases showed 
leakage till the end of the study. 
CONCLUSIONS 
Intravitreal bevacizumab (1.25 mg) treatment is well tolerated 
over 6 months with significant safety and efficacy.   
Nevertheless, this is a small interventional study, with no 
comparison arm to quantify the actual magnitude of benefit of this 
treatment modality compared with other therapies.  
This would have to be studied subsequently in larger studies and 
also needs to be compared with other VEGF inhibitiors regarding safety 
and efficacy. 
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PROFORMA 
 
Case-no: 
Name                       Age                 Sex            Occupation           OP no. 
Address                                                            Phone No.  
Chief complaints  
• Defective vision 
• Distorted vision 
• Pain in the eye 
Past history: 
*Diabetes  -  no o years 
                 - type I / II 
                 -  On oral hypoglycemics / Insulin 
                 -  Whether blood sugar under control 
                 -  associated with NVG 
                 -  PRP given / not 
                     If given – no of sittings 
*Hypertension - No of years 
                        - On what medication 
                        - Associated with ischemic heart disease/hyper 
lipidemia / cerebrovascular insult 
*H/O smoking 
On systemic examination: 
            PR:                                                         BP: 
           RBS:                                         Urine – alb & sugar: 
         HbA1c: 
On ocular examination: 
                                                 RE                                     LE 
Visual acuity           -- 
Tension (By NCT)  -- 
Conjunctiva             -- 
Cornea                     -- 
Iris                           --                 
Ant.chamber            -- 
Lens                         -- 
Slit lamp Ex            -- 
Fields                      -- 
Colour vision           -- 
Fundus by 90D        
Fundus by IDO 
FUNDUS FLUORESCEIN ANGIOGRAPHY: 
Amsler’s grid chart: 
Optical coherence tomography: 
Diagnosis: 
Treatment history: 
           Under aseptic conditions, under topical anaesthesia, inj. 
Bevacizumab 1.25mg is injected intravitreally. 
         No.of sittings          -             Date 
 
Outcome of treatment: 
MASTER CHART 
PRE-PROCEDURE 
POST - PROCEDURE 
4 weeks 8 weeks 12 weeks          16 weeks 
NAME SEX 
IP. 
NO 
Diagnosis 
Vision OCT FFA V/A OCT FFA V/A 
OC
T 
FFA V/A OCT FFA 
V/A 
OCT FFA 
Nagammal f 67894 RE-CNV 4/60ph5/60 160 + 5/60 PH 6/60 155 + 6/60 PH 6/36 145 _ 6/36 NIP 134 _ 6/36 NIP 122 _ 
Ganesan m 45632 RE-CNV 3/60PH4/60 174 + 4/60 NIP 170 + 3/60 NIP 165 _ 3/60 PH 4/60 144 _ 3/60 PH 4/60 111 _ 
Anushya f 67865 LE-PDR HM 387 + HM 387 + CFCF 322 + 1/60 NIP 287 _ 2/60 NIPS 245 + 
sarathy f 56784 RE-CNV 2/60PH 6/60 189 _ 2/60 PH 3/60 176 + 4/60 PH 6/36 166 _ 5/60 NIP 144 _ 5/60 PH 6/60 122 _ 
Sivagami f 76584 LE-CNV 1/60 PH 4/60 278 + 3/60 PH 5/60 255 + 4/60 PH 6/36 234 + 4/60 PH 6/36 213 _ 4/60 PH 6/36 197 _ 
Janaki f 87695 LE-CNV HM 345 + HM 330 _ CFCF 300 + 1/60 NIP 267 + 1/60 NIP 222 _ 
Devid m 78659 RE-CNV HM 335 + 1/60NIP 300 + 2/60 NIP 280 + 2/60 NIP 245 _ 2/60 PH 3/60 210 _ 
Umapathy m 78654 RE-CNV 5/60 PH 6/60 298 + 6/60 PH 6/36 278 + 5/60 PH 6/36 245 _ 5/60 PH 6/36 234 _ 5/60 PH 6/60 197 _ 
Thilagar m 76589 LE-CNV 2/60 PH 3/60 300 + 3/60 PH 5/60 245 + 4/60 PH 6/36 233 _ 5/60 PH 6/60 213 _ 5/60 PH 6/60 200 _ 
Kasthuri f 73099 RE-CNV 1/60 NIP 269 + 2/60 NIP 255 + 4/60 PH 6/60 222 + 4/60 PH 6/60 198 _ 4/60 PH 6/36 278 + 
Shanthi f 87695 LE-CNV HM 397 + 1/60 PH 2/60 345 + 2/60 PH 6/60 298 + 3/60 NIP 165 _ 3/60 PH 6/60 255 _ 
Hussain m 67895 RE-CNV HM 456 + HM 432 + 1/60 PH 6/60 389 + 1/60 PH 3/60 355 + 1/60 PH 3/60 322 + 
Lakshman m 78594 RE-CNV 1/60NIP 487 + 2/60 PH 3/60 487 + 3/6O NIP 400 + 3/60 NIP 366 + 3/6O NIP 314 _ 
Nagarajan m 78659 RE-CRVO 1/6O 246 + 1/60 PH 2/60 246 _ 2/60 PH 6/60 222 _ 2/60 PH 5/60 203 _ 3/60 NIP 192 _ 
Samasath m 89765 LE-CNV 2/60 NIP 376 + 2/60NIP 376 + 3/60 PH 6/60 344 + 3/60 PH 6/60 312 + 4/60 PH 6/60 278 + 
Rahmadulla m 87965 RE-PDR 1/60 NIP 220 + 1/60 NIP 220 _ 2/60 PH 6/60 198 _ 2/60 PH 6/60 220 _ 2/60 PH 6/60 220 _ 
Meera moid m 87650 LE-CNV 4/60 PH 6/60 378 + 5/60 PH 6/60 365 + 6/60 NIP 320 + 5/60 NIP 287 _ 5/60 NIP 256 _ 
Abdulkader m 78596 RE-CNV 6/60 PH 6/24 269 + 6/36 PH 6/18 260 + 6/24 PH 6/18 220 _ 6/24 PH 6/18 198 _ 6/24 PH 6/18 177 _ 
Janardanan m 83459 RE-CNV 5/60 PH 6/36 255 + 6/60 PH 6/36 250 + 6/36 PH 6/18 211 _ 6/36 PH 6/12 187 _ 6/36 PH 6/24 168 _ 
Srinivasalu m 76859 LE-CNV 1/60 PH 4/60 289 + 2/60 PH 3/60 280 + 6/36 PH 6/24 234 _ 6/36 PH 6/24 213 - 6/36 PH 6/24 191 _ 
Indirani f 85420 LE-PDR 3/60 PH 6/60 146 + 6/60 PH 6/36 122 _ 6/36 PH 6/24 111 _ 6/24 NIP 98 _ 6/24 PH 6/18 97 _ 
Ameer m 81234 RE-CNV 2/60 PH 6/60 278 + 3/60 PH 6/36 270 + 5/60 PH 6/36 234 _ 6/60 PH 6/24 198 - 6/60 PH 6/18 188 _ 
Durairaj m 56748 LE-CNV 1/60 PH 3/60 345 + 2/60 PH 4/60 340 + 3/60 PH 6/60 287 + 4/60 PH 6/36 234 _ 4/60 PH 6/60 212 _ 
Berkman m 76850 RE-CNV 2/60 PH 6/60 378 + 3/60 NIP 368 + 4/60 PH 5/60 311 + 6/60 NIP 267 = 6/60 PH 6/36 234 _ 
Saraswathy f 63095 LE-CRVO HM 246 + 1/60 NIP 246 + 3/60 PH  6/36 201 _ 4/60 PH 6/24 189 _ 4/60 PH 6/24 166 _ 
Santhanam m 75803 RE-CNV 6/60 PH 6/36 255 + 6/60 PH 6/24 245 _ 6/36 PH 6/24 203 _ 6/36 PH 6/24 197 _ 6/36 PH 6/24 169 _ 
Saraswathy f 80587 RE-CNV HM 398 + CFCF 378 + 1/60 NIP 322 + 2/60 NIP 287 + 3/60 NIP 234 _ 
Baby f 76894 LE-CNV HM 467 + CFCF 455 + CFCF 389 + CFCF 322 + CFCF 289 + 
Dhanam f 60498 RE-CNV 3/60 PH 6/60 345 + 4/60 NIP 340 + 3/60 PH 6/60 340 + 4/60 PH 6/36 298 + 4/60 PH 6/36 277 _ 
Kannappan m 86750 LE-CNV 2/60 NIP 453 + 1/60 NIP 435 + 2/60 NIP 435 + 2/60 NIP 367 + 2/60 NIP 370 + 
Kumary f 82635 RE-CNV 5/60 PH 6/36 267 + 6/60 PH 6/24 255 _ 6/36 PH 6/24 222 _ 6/36 PH 6/24 178 _ 6/36 PH 6/24 166 _ 
Rameshwari f 89463 LE-CNV 3/60 PH 6/60 346 + 2/60 PH 6/36 345 + 6/36 NIP 302 + 6/36 PH 6/24 278 + 6/36 PH 6/24 234 _ 
Krishnan m 82176 RE-PDR 1/60 PH 2/60 378 + /60 NIP 378 + 3/60 PH 4/60 342 + 4/60 NIP 302 + 4/60 NIP 355 + 
Saroja f 67580 LE-CNV 4/60NIP 8 + 5/60 PH 6/36 276 + 6/60 PH 6/36 245 _ 6/60 PH 6/24 213 _ 6/60 PH 6/24 194 _ 
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KEY TO MASTER CHART 
 
OCT – Optical coherence tomography 
 
FFA – Fundus Fluorescein Angiography 
 
PDR - Proliferative Diabetic Retinopathy 
 
CRVO – Central retinal Vein Occlusion 
 
CNV  –  Choroidal Neovascularization. 
 
V/A - Visual acuity  
 
PH - Pinhole 
 
 2 
LIST OF SURGERIES PERFORMED 
 
S. 
No. 
Name Age Sex IP no. Diagnosis Surgeries 
1. Kanniammal 60 F 684392 BE IMC LE ECCE with PCIOL 
2. Maragatham 65 F 785391 RE IMC/LE MC LE ECCE with PCIOL 
3. Elangovan 76 M 790160 RE IMC/LE MC LE ECCE with PI 
4. perumal 70 M 690437 RE IMC/LE MC LE ECCE with PCIOL 
5. Jayagopal 50 M 692899 BE IMC RE ECCE with PCIOL 
6. Subramani 57 M 793525 RE IMC/LE MC LE ECCE with PCIOL 
7. Kaliammal 68 F 783728 BE Nuclear Cat. RE ECCE with PCIOL 
8. Annammal 60 F 674267 BE MC LE ECCE with PCIOL 
9. Krishnaveni 50 F 725015 BE IMC LE SICS  with PCIOL 
10. Muniyammal 65 F 816095 BE IMC LE SICS with PCIOL 
11. Dhanalakshmi 46 F 785885 BE IMC RE SICS with PCIOL 
12. Ramasamy 65 M 826095 BE IMC RE SICS with PCIOL 
13. Vasantha 38 F 656005 RE PSEUDO/ LE 
IMC 
LE ECCE with PCIOL 
14. Gopal 65 M 776441 BE IMC LE SICS with PCIOL 
15. Chandra 65 F 886336 RE MC/ LE PSEUDO RE SICS with PCIOL 
16. Vellaiyan 55 M 847637 BE MC LE ECCE with PCIOL 
17. Dasappan 35 M 87720 LE EXP. KERATITIS LEMEDIAL  
TARSORRAPHY 
18. Etiappan 58 M 891721 LE-IMC LE – SICS with PCIOL 
19. Mariappan 52 M 792726 LE-IMC LE – SICS with PCIOL 
20. Shanthi 48 F 811986 BE IMC RE SICS with PCIOL 
21. Varadhan 46 M 820826 RE  CDC RE DCR 
22. Sumathy 54 F 762091 LE CDC LE DCT 
23. Baskar 52 M 83940 RE-Matur Cataract  RE – SICS with PCIOL 
24 Venkatesh 56 M 78542 LE-IMC LE – SICS 
25. Lakshmi 72 F 84286 RE CDC RE -  DCT 
 
